AcuCort CEO presents the company

03 March 2020 - 09:47
AcuCort develops and commercializes ISICORT ‒ a new fast-dissolving oral film to be put on the tongue, based on a well-known version of cortisone – dexamethasone. ISICORT is a smart product in a new, innovative and user-friendly administration form, primarily for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV)....
Spotlight (Sweden)
AcuCort AB
AcuCort operates within medical technology. The company develops fast-dissolving oral films with specific chemical substances that are used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. The products can be used by both children and adults. The main part of the business is within the Nordic markets. AcuCort was founded in 2006 and...
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date